UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/643,627	08/19/2003	Johan Sundelin	MPI93-006CP1DV1ACN1DV1M	4455

50446 7590 01/11/2006

HOXIE & TSO LLP
374 MILLBURN AVENUE
SUITE 300 E
MILLBURN, NJ 07041

EXAMINER	
GUZO, DAVID	

ART UNIT	PAPER NUMBER
1636	

DATE MAILED: 01/11/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/643,627	SUNDELIN ET AL.	
	Examiner	Art Unit	
	David Guzo	1636	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *6/30/05; 10/24/05*.

2a)☒ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *27,28 and 44-58* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☒ Claim(s) *46,47 and 53-58* is/are allowed.

6)☒ Claim(s) *27,28,44,45 and 48-52* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date *6/30/05*.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☒ Other: *See Continuation Sheet*.

Continuation of Attachment(s) 6). Other: Raw Sequence Error Report; Notice to Comply with the Sequence Rules.

Detailed Action

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). A computer readable form (CRF) of the sequence listing was submitted. However, the following errors were detected by the Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC), said errors are set forth on the attached RAW SEQUENCE LISTING ERROR REPORT and Notice to Comply with the Sequence Rules.

Applicant must comply with the sequence rules, 37 CFR 1.821 - 1.825. Applicant is requested to return a copy of the attached RAW SEQUENCE LISTING ERROR REPORT with the reply. Any reply to this Office Action which does not include complete compliance with the Sequence Rules will be considered non-responsive.

Applicants' amendment of the first page of the specification to recite the priority claim is acknowledged.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

> The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 27, 28, 44, 45 and 48-52 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to

reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Applicants have amended claims 27 and 44 to recite that the C140 receptor polypeptide "has cross-reactive antigenicity to at least 15 amino acids of the amino acid sequence of SEQ ID NO:4 or SEQ ID NO:63". Applicants, in the Remarks filed 6/30/05, indicate that specific support for the amendments to the claims can be found on pages 12 and 13 of the specification as well as throughout the specification and claims as originally filed. The examiner can find no support for the specific claimed limitation at the specific portion of the specification indicated by applicants. While page 13 of the specification recites:

> The novel proteins and peptides of the present invention are preferably those which share a common biological activity with the C140 receptor, including but not limited to an effector or receptor function or cross-reactive antigenicity.

the specification does not disclose the specific limitation that the C140 receptor polypeptide has cross-reactive antigenicity to a specifically delineated portion (at least 15 amino acids) of SEQ ID NO:4 or SEQ ID NO:63. The remainder of the originally filed specification and originally filed claims makes no reference to antigenicity of the C140 receptor proteins and peptides. This is a NEW MATTER rejection necessitated by applicant's amendment.

Claims 27-28 and 50-52 rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to

one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

This rejection is maintained for reasons of record in the previous Office Action (Mailed 4/6/05) and for reasons outlined below. The rejection is expanded to include new claims 50-52 as a result of applicants' amendment filed 6/30/05.

Applicants traverse this rejection by asserting that they have provided an alignment of the human and murine C140 receptors and have shown high homology and conserved regions including a transmembrane domain, signal peptides, proteolytic cleavage sites, etc. and therefore have provided two examples of the claimed invention with structural information. Applicants indicate that the amendment of claim 27 to recite that the polypeptide has cross-reactive antigenicity to at least 15 amino acids of SEQ ID NO:4 or 63 provides a relevant identifying characteristic in the form of a structural limitation and that the above properties in combination with the sequences of SEQ ID NO:3-4 and 62-63 as well as the nucleotide sequences which hybridize under stringent conditions to SEQ ID NOs 3 or 62 and encode polypeptides of at least 15 amino acids in length which have cross-reactivity with SEQ ID NO:4 or 63 provide evidence that they had possession of the claimed invention.

Applicant's arguments filed 6/30/05 have been fully considered but they are not persuasive. With regard to the alignment between the human and murine C140 proteins, it is noted that applicants have identified **putative** cleavage sites and activation peptides as well as putative signal peptides and a transmembrane domain. However, applicants have not definitively identified regions essential for any of the

specific biological activities of the C140 molecule as a G protein coupled receptor. Given the broad definition of the genus of molecules which is encompassed by the term "C140 receptor polypeptides" (See previous Office Action, p. 5) and given the absence of information on the specific regions of the molecule responsible for specific biological activities of the molecule, it must be considered that the presentation of two species does not represent a sufficient number of species to describe the claimed genus.

With regard to the arguments that recitation of the limitation of cross-reactive antigenicity to at least 15 amino acids of SEQ ID NO:4 or 63 imparts a structural limitation, it is noted that this merely provides a structure-function relationship between 15 amino acid residues of a molecule of more than 300 amino acids in length and the claimed C140 polypeptide. This limitation provides no structure-function relationship between the claimed C140 polypeptide and the remainder of SEQ ID NO:4 or 63. It is noted that the amended claims read on any isolated C140 polypeptide having at least 15 consecutive amino acid residues and is encoded by a nucleic acid capable of hybridizing under somewhat stringent conditions to complements of SEQ ID NOs 3 and 62. Indeed, the results of this hybridization encompass a broad range of polypeptides which can be only about 75% identical to SEQ ID NOs 4 or 53 (see claim 28). Therefore it must be considered, absent evidence to the contrary, that the two species of C140 molecules disclosed by applicants do not represent a sufficient number of species to persuade the skilled artisan that applicants were in possession of the claimed genus.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

> The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 27-28, 44-45 and 48-52 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 27 (and dependent claims) is vague in the recitation of the phrase "polypeptide having a consecutive sequence of at least 15 amino acids" as it is unclear what a "consecutive sequence" is. Possibly applicants mean to recite a sequence "of at least 15 consecutive amino acids" as this makes more sense. Claim 27 (and claim 44) are also vague in the recitation of a polypeptide that has cross-reactive antigenicity to "at least 15 amino acids" of the recited SEQ ID NOs. It is unclear if the at least 15 amino acids are consecutive amino acids or individual amino acids scattered throughout the recited C140 protein.

Claim 50 is vague in the recitation of "amino acid sequence identity with either of SEQ ID NO:4." because there are no other sequences recited in the claim.

Claim 51 is vague in the recitation of "amino acid sequence identity with either of SEQ ID NO:63." because there are no other sequences recited in the claim.

Any rejections not repeated in this Office Action are withdrawn.

Claims 46-47 and 53-58 are allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Guzo, Ph.D., whose telephone number is (571) 272-0767. The examiner can normally be reached on Monday-Thursday from 8:00 AM to 5:30 PM. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Irem Yucel, Ph.D., can be reached on (571) 272-0781. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

David Guzo
December 28, 2005

DAVID GUZO
PRIMARY EXAMINER

Notice to Comply	Application No. 10/643,627	Applicant(s) Sundelin et al.	
	Examiner David Guzo	Art Unit 1636	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

☐ 7. Other:

Applicant Must Provide:

☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

☒ An initial or substitute paper copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.**

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923
For CRF Submission Help, call (703) 308-4212 or 308-2923
PatentIn Software Program Support
Technical Assistance.....703-287-0200
To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

STIC Biotechnology Systems Branch

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/643,627A
Source: IFW16
Date Processed by STIC: 10/27/05

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:
1) **INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,**
2) **TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY**

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, **PLEASE** USE THE **CHECKER VERSION 4.2.2 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.
Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.
Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm> , **EFS Submission User Manual** - ePAVE)
2. **U.S. Postal Service:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. **Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):** U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/24/05

IFW16

RAW SEQUENCE LISTING DATE: 10/27/2005
PATENT APPLICATION: US/10/643,627A TIME: 11:55:18

Input Set : A:\sequence listing.txt
Output Set: N:\CRF4\10272005\J643627A.raw

```
  3 <110> APPLICANT: Sundelin, Johan
  4       Scarborough, Robert M.
  6 <120> TITLE OF INVENTION: Recombinant C140 Receptor, Its Agonists and Antagonists, and
  7       Nucleic Acids Encoding the Receptor
  9 <130> FILE REFERENCE: 44481-5006-09-US
 11 <140> CURRENT APPLICATION NUMBER: US 10/643,627A
 12 <141> CURRENT FILING DATE: 2003-08-19
 14 <150> PRIOR APPLICATION NUMBER: US 10/127,691
 15 <151> PRIOR FILING DATE: 2002-04-23
 17 <150> PRIOR APPLICATION NUMBER: US 08/097,938
 18 <151> PRIOR FILING DATE: 1993-07-26
 20 <150> PRIOR APPLICATION NUMBER: US 08/390,301
 21 <151> PRIOR FILING DATE: 1995-01-25
 23 <150> PRIOR APPLICATION NUMBER: US 08/474,414
 24 <151> PRIOR FILING DATE: 1995-06-07
 26 <160> NUMBER OF SEQ ID NOS: 64
 28 <170> SOFTWARE: PatentIn Ver. 2.1
```

Does Not Comply
Corrected Diskette Needed

ERRORED SEQUENCES

```
1979 <210> SEQ ID NO: 64
1980 <211> LENGTH: 424
1981 <212> TYPE: PRT
1982 <213> ORGANISM: Homo sapiens
1984 <400> SEQUENCE: 64
1985   Met Gly Pro Arg Arg Leu Leu Leu Val Ala Ala Cys Phe Ser Leu Cys
1986     1               5                  10                  15
1988   Gly Pro Leu Leu Ser Ala Arg Thr Arg Ala Arg Arg Pro Glu Ser Lys
1989                20                  25                  30
1991   Ala Thr Asn Ala Thr Leu Asp Pro Arg Ser Phe Leu Leu Arg Asn Pro
1992            35                  40                  45
1994   Asn Asp Lys Tyr Glu Pro Glu Trp Glu Asp Glu Glu Lys Asn Glu Ser
1995        50                  55                  60
1997   Gly Leu Thr Glu Tyr Arg Leu Val Ser Ile Asn Lys Ser Ser Pro Leu
1998    65                  70                  75                  80
2000   Gln Lys Gln Leu Pro Ala Phe Ile Ser Glu Asp Ala Ser Gly Tyr Leu
2001                85                  90                  95
2003   Thr Ser Ser Trp Leu Thr Leu Phe Val Pro Ser Val Tyr Thr Gly Val
2004            100                 105                 110
2006   Phe Val Val Ser Leu Pro Leu Asn Ile Met Ala Ile Val Val Phe Ile
2007          115                 120                 125
2009   Leu Lys Met Lys Val Lys Lys Pro Ala Val Val Tyr Met Leu His Leu
```

425 shown (p.2)

RAW SEQUENCE LISTING DATE: 10/27/2005
PATENT APPLICATION: US/10/643,627A TIME: 11:55:18

Input Set : A:\sequence listing.txt
Output Set: N:\CRF4\10272005\J643627A.raw

```
2010       130                 135                 140
2012   Ala Thr Ala Asp Val Leu Phe Val Ser Val Leu Pro Phe Lys Ile Ser
2013   145                 150                 155                 160
2015   Tyr Tyr Phe Ser Gly Ser Asp Trp Gln Phe Gly Ser Glu Leu Cys Arg
2016                   165                 170                 175
2018   Phe Val Thr Ala Ala Phe Tyr Cys Asn Met Tyr Ala Ser Ile Leu Leu
2019               180                 185                 190
2021   Met Thr Val Ile Ser Ile Asp Arg Phe Leu Ala Val Val Tyr Pro Met
2022           195                 200                 205
2024   Gln Ser Leu Ser Trp Arg Thr Leu Gly Arg Ala Ser Phe Thr Cys Leu
2025       210                 215                 220
2027   Ala Ile Trp Ala Leu Ala Ile Ala Gly Val Val Pro Leu Val Leu Lys
2028   225                 230                 235                 240
2030   Glu Gln Thr Ile Gln Val Pro Gly Leu Asn Ile Thr Thr Cys His Asp
2031                   245                 250                 255
2033   Val Leu Asn Glu Thr Leu Leu Glu Gly Tyr Tyr Ala Tyr Tyr Phe Ser
2034               260                 265                 270
2036   Ala Phe Ser Ala Val Phe Phe Phe Val Pro Leu Ile Ile Ser Thr Val
2037           275                 280                 285
2039   Cys Tyr Val Ser Ile Ile Arg Cys Leu Ser Ser Ser Ala Val Ala Asn
2040       290                 295                 300
2042   Arg Ser Lys Lys Ser Arg Ala Leu Phe Leu Ser Ala Ala Val Phe Cys
2043   305                 310                 315                 320
2045   Ile Phe Ile Ile Cys Phe Gly Pro Thr Asn Val Leu Leu Ile Ala His
2046                   325                 330                 335
2048   Tyr Ser Phe Leu Ser His Thr Ser Thr Thr Glu Ala Ala Tyr Phe Ala
2049               340                 345                 350
2051   Tyr Leu Leu Cys Val Cys Val Ser Ser Ile Ser Ser Cys Ile Asp Pro
2052           355                 360                 365
2054   Leu Ile Tyr Tyr Tyr Ala Ser Ser Glu Cys Gln Arg Tyr Val Tyr Ser
2055       370                 375                 380
2057   Ile Leu Cys Cys Lys Glu Ser Ser Asp Pro Ser Ser Tyr Asn Ser Ser
2058   385                 390                 395                 400
2060   Gly Gln Leu Met Ala Ser Lys Met Asp Thr Cys Ser Ser Asn Leu Asn
2061                   405                 410                 415
2063   Asn Ser Ile Tyr Lys Lys Leu Leu Thr
E--> 2064           420 420
```

VERIFICATION SUMMARY DATE: 10/27/2005
PATENT APPLICATION: US/10/643,627A TIME: 11:55:19

Input Set : A:\sequence listing.txt
Output Set: N:\CRF4\10272005\J643627A.raw

L:727 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9 after pos.:0
L:746 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10 after pos.:0
L:766 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11 after pos.:0
L:786 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12 after pos.:0
L:805 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13 after pos.:0
L:824 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14 after pos.:0
L:843 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:15 after pos.:0
L:862 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16 after pos.:0
L:881 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:17 after pos.:0
L:900 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:18 after pos.:0
L:1358 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:50 after pos.:0
L:1377 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:51 after pos.:0
L:1397 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:52 after pos.:0
L:1417 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:53 after pos.:0
L:1464 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:56 after pos.:0
L:1483 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:57 after pos.:0
L:1503 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:58 after pos.:0
L:1523 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:59 after pos.:0
L:2064 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:64
L:2064 M:252 E: No. of Seq. differs, <211> LENGTH:Input:424 Found:425 SEQ:64